Assessment of Oral Anticancer Medicines in Pediatric Patients before the Research to Accelerate Cures and Equity (RACE) Act, 2007-2021
Year: 2025
Type: article
Language: en
Topic: Pharmaceutical studies and practices
Authors and affiliations:
raw_author_name: Mahnum Shahzad
raw_affiliation_strings: Department of Population Medicine, Harvard Medical School, Boston, MA; Harvard Pilgrim Health Care Institute, Boston, MA; Pharmaceutical Policy Lab, LSE Health, The London School of Economics and Political Science, London, United Kingdom. Electronic address: Mahnum_shahzad@g.harvard.edu
Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA; Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA; Pharmaceutical Policy Lab, LSE Health, The London School of Economics and Political Science, London, UK. Electronic address: Mahnum_shahzad@g.harvard.edu
raw_author_name: Steven G. DuBois
raw_affiliation_strings: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Department of Pediatrics, Harvard Medical School, Boston, MA
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA
raw_author_name: Rebecca Costa
raw_affiliation_strings: Harvard Pilgrim Health Care Institute, Boston, MA
Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA
raw_author_name: Stephanie Argetsinger
raw_affiliation_strings: Harvard Pilgrim Health Care Institute, Boston, MA
Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA
raw_author_name: Dennis Ross-Degnan
raw_affiliation_strings: Department of Population Medicine, Harvard Medical School, Boston, MA; Harvard Pilgrim Health Care Institute, Boston, MA
Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA; Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA
raw_author_name: Florence T. Bourgeois
raw_affiliation_strings: Pharmaceutical Policy Lab, LSE Health, The London School of Economics and Political Science, London, United Kingdom; Department of Pediatrics, Harvard Medical School, Boston, MA; Pediatric Therapeutics and Regulatory Science Initiative, Computational Health Informatics Program, Boston Children's Hospital, Boston, MA; Harvard-MIT Center for Regulatory Science and Department of Pediatrics, Harvard Medical School, Boston, MA
Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA; Pediatric Therapeutics and Regulatory Science Initiative, Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts, USA; Harvard-MIT Center for Regulatory Science and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA; Pharmaceutical Policy Lab, LSE Health, The London School of Economics and Political Science, London, UK
raw_author_name: Anita K. Wagner
raw_affiliation_strings: Department of Population Medicine, Harvard Medical School, Boston, MA; Harvard Pilgrim Health Care Institute, Boston, MA; Pharmaceutical Policy Lab, LSE Health, The London School of Economics and Political Science, London, United Kingdom
Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA; Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA; Pharmaceutical Policy Lab, LSE Health, The London School of Economics and Political Science, London, UK